Statistics from Altmetric.com
In the pandemic of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) disease 2019 (COVID-19), patients with immunosuppressive therapies have a potentially more severe course of the disease. While recent data from the registry of the Global Rheumatology Alliance have been reassuring regarding the use of biological disease-modifying antirheumatic drugs (bDMARDs), no definite recommendations can be made regarding specific bDMARDs.1 In their recent letter, Nuño and coworkers describe a large cohort of 122 patients with rheumatic diseases.2 Most interestingly, higher hospitalisation rates and more severe and life-threatening cases of COVID-19 have been described with the use of rituximab (RTX).2–4 To the best of our knowledge, we here describe the first reported case with repeated false-negative tests and a delayed diagnosis of COVID-19 in a patient with granulomatosis with polyangiitis (GPA) under maintenance therapy with RTX and concomitant influenza pneumonia.
An 80-year-old man presented to the emergency department with a 2-week history of productive cough. The patient had received a diagnosis of GPA in 2014 with biopsy-confirmed renal vasculitis and no history of pulmonary manifestation. After remission induction, he received RTX at a dose of 500 mg every 6 months as maintenance therapy. A staging CT of the chest 2 weeks prior to admission had shown only minor orthostatic congestion (figure 1A and B). On admission, chest radiography (CXR) showed mild pulmonary-venous congestion without consolidation (figure 1C). A nasopharyngeal swab was negative for SARS-CoV-2 but positive for influenza A RNA, and antiviral therapy with oseltamivir was initiated. Oxygen and ampicillin/sulbactam for suspected bacterial superinfection were administered and the patient was admitted to a medical ward. Due to progressive respiratory failure, he was transferred to the intermediate care unit and a follow-up CXR showed considerable congestion and superimposed consolidation (figure 1D). Antibiotic treatment was escalated to piperacillin/tazobactam and clarithromycin. Because of worsening respiratory failure, the patient was transferred to the intensive care unit (ICU) requiring non-invasive-assisted ventilation. Considering his deteriorating renal function, haemoptysis and another negative nasopharyngeal swab for SARS-CoV-2 RNA, a flare-up of GPA was suspected and glucocorticoids with therapeutic plasma exchange were initiated. Consecutive CT scans of the lungs showed bilateral ground-glass opacities and consolidation compatible with COVID-19 or a pulmonary manifestation of GPA (figure 1E). Based on these imaging findings, another nasopharyngeal swab was obtained but returned negative for SARS-CoV-2 RNA. However, tracheal aspirate was found to be positive for COVID-19. Glucocorticoid therapy and plasma exchange were discontinued and the patient was transferred to the dedicated ICU for COVID-19 cases. Subsequently, the patient expired due to multiorgan failure.
In this patient, repeated nasopharyngeal swabs for SARS-CoV-2 RNA yielded negative results, but a tracheal aspirate ultimately confirmed COVID-19. Postmortem analysis of the lungs confirmed COVID-19 and influenza pneumonia with no signs of a GPA flare-up (figure 1F–I). It remains unclear why, although repeatedly performed, nasopharyngeal swabs for SARS-CoV-2 RNA were all negative in our case. A possible explanation is that the patient’s immunocompromised state may have contributed and we recommend caution with the use of RTX until more granular data regarding its safety are available. While test availability has been a concern during the COVID-19 pandemic, test accuracy has most recently become an equal matter of debate.5 6 The difficulties encountered in the differential diagnosis in this case emphasise the need for a clear sense of the performance of SARS-CoV-2 RNA testing in the context of clinical decision-making in cases with multiple causes for respiratory failure and use of bDMARDs in immunocompromised patients.
Contributors BT conceived the correspondence and wrote the first draft. SH and JF collected pathology specimens and performed histological analysis. JL contributed and interpreted radiology images. PK and MSW provided clinical data. All authors participated in the construction and editing of the manuscript. Compassionate use was approved by our local ethics committee at the University of Göttingen and informed consent for publication was obtained from the patient’s family.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.
Patient consent for publication Next of kin consent obtained.
Provenance and peer review Not commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.